Get started
Author

Christoph Kneip

Observed names: C Kneip, C. Kneip, Kneip, Christoph
Institution: Bayer (Germany)
ORCID: 0000-0002-9386-9420
Observed ORCID: 0000-0002-9386-9420
OpenAlex ID: A5054705080
SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma
2011 · Christoph Kneip, Bernd Schmidt, et al. · Journal of Thoracic Oncology · 269
Nitrogen fixation in eukaryotes – New models for symbiosis
2007 · Christoph Kneip, Peter Lockhart, et al. · BMC Evolutionary Biology · 259
PDF
SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates
2010 · Bernd Schmidt, Volker Liebenberg, et al. · BMC Cancer · 205
PDF
Intracellular Spheroid Bodies of Rhopalodia gibba Have Nitrogen-Fixing Apparatus of Cyanobacterial Origin
2004 · Julia Prechtl, Christoph Kneip, et al. · Molecular Biology and Evolution · 154
PDF
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
2019 · Urs B. Hagemann, Christine Ellingsen, et al. · Clinical Cancer Research · 117
Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
2016 · Tobias M. Gorges, Sabine Riethdorf, et al. · Oncotarget · 106
PDF
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
2019 · Sylvia Grünewald, Oliver Politz, et al. · International Journal of Cancer · 98
PDF
The cyanobacterial endosymbiont of the unicellular algae Rhopalodia gibba shows reductive genome evolution
2008 · Christoph Kneip, Christine Voβ, et al. · BMC Evolutionary Biology · 96
PDF
Correlation of SHOX2 Gene Amplification and DNA Methylation in Lung Cancer Tumors
2011 · Katja U Schneider, Dimo Dietrich, et al. · BMC Cancer · 74
PDF
Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology
2016 · Lilla Landeck, Christoph Kneip, et al. · Experimental Dermatology · 60
PDF
Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
2017 · Jörg Willuda, Lars Linden, et al. · Molecular Cancer Therapeutics · 45
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
2019 · Franck Morschhauser, Jean-Pascal Machiels, et al. · Molecular Cancer Therapeutics · 40
PDF
Confidence-based Somatic Mutation Evaluation and Prioritization
2012 · Martin Löwer, Bernhard Y. Renard, et al. · PLoS Computational Biology · 33
PDF
Tackling the intractable – Approaching the genetics of Chlamydiales
2007 · Dagmar Heuer, Christoph Kneip, et al. · International Journal of Medical Microbiology · 19
A novel method for sensitive and specific detection of DNA methylation biomarkers based on DNA restriction during PCR cycling
2009 · Christoph Kneip, Bernd Schmidt, et al. · BioTechniques · 16
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
2024 · Kyriakos P. Papadopoulos, Meredith McKean, et al. · Clinical Cancer Research · 12
PDF
Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland
2020 · David Vizcaya, Bahman Farahmand, et al. · Cancer Treatment and Research Communications · 12
PDF
Development and performance evaluation of a CE-IVD for measuring SHOX2 DNA methylation in bronchial aspirates for the diagnosis of lung cancer
2012 · Dimo Dietrich, Volker Liebenberg, et al. · Lung Cancer · 3
Data from First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
2024 · Kyriakos P. Papadopoulos, Meredith McKean, et al. · 1
Abstract 3738: Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877
2017 · Peter Ellinghaus, Matthias Ocker, et al. · Cancer Research · 1
Supplementary Data 1 from First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
2024 · Kyriakos P. Papadopoulos, Meredith McKean, et al.
Figure S4 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
2023 · Franck Morschhauser, Jean-Pascal Machiels, et al.
PDF
Figure S2 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
2023 · Franck Morschhauser, Jean-Pascal Machiels, et al.
Supplementary materials and methods from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
2023 · Franck Morschhauser, Jean-Pascal Machiels, et al.
Table S3 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
2023 · Franck Morschhauser, Jean-Pascal Machiels, et al.
PDF
Works count: 96
Citation count: 1,620
H-index: 15
I10-index: 17
Year
Topic
Type